Anesthesia Tumescent for Surgical Management of Tenosynovitis.

Overview

The aim of this study is to evaluate the effectiveness of the tumescent anesthesia technique in the surgical management of hand tenosynovitis. For this, an open clinical trial was conducted, which included patients with hand tenosynovitis (carpal tunnel syndrome, trigger finger and Quervain syndrome), which were randomly assigned to a group. The control group was released pulleys and ligaments with local anesthetic technique and hemostasis with pneumatic tourniquet; While the study group was released from the pulleys and ligaments with tumescent anesthesia. The study variables were: anesthesia time, trans-surgical bleeding, pain, total procedure time and tissue reperfusion time.

Full Title of Study: “Efficacy of Tumescent Local Anesthesia in the Surgical Management of Tenosynovitis.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 31, 2019

Detailed Description

Introduction: The WALANT technique (Wide Awake Local Anesthesia No-Torniquet) proposes the use of local anesthesia, epinephrine and tourniquet in the areas of the hand to be repaired, making costs and time and comfort more efficient. Objective: Evaluation of the effectiveness of the WALANT technique versus regional anesthesia with tourniquet in pain control, surgical management of stenosing tenosynovitis. Material and methods: Open clinical trial including patients with the trigger finger, tunnel syndrome in the operating room, candidates for surgery, and excluding previous surgeries at the site of the injury, hemodynamic instability, peripheral vascular diseases, smoking, anxiety, or psychiatric diseases. The anesthetic method was applied to the incision sites according to the diagnosis and the proposed procedure. At the end of the test, tumescent solution and control, 1% lidocaine plus pneumatic tourniquet on the forearm at 250mmHg. The main variables were: type of anesthesia and pain during the procedure. Descriptive and inferential statistics were applied (xi2, t-student or Mann-Whitney U).

Interventions

  • Combination Product: Tumescent Anesthesia
    • A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.
  • Drug: Lidocaine
    • Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).
  • Device: Pneumatic tourniquet
    • Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.
  • Procedure: Open release of the tendon
    • Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.

Arms, Groups and Cohorts

  • Experimental: Tumescent anesthesia
    • A tumescent solution was prepared; consisting of 40 cc of 0.9% Saline Solution, 10 cc of 2% Lidocaine, 0.4 cc of Epinephrine (1: 1000) and 4 cc of 7.5% Sodium Bicarbonate. This solution was applied in the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc of tumescent solution was injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc of tumescent solution was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Subsequently, 20 minutes were waited for the epinephrine to cause vasoconstriction, and the asepsis of the limb was continued , sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
  • Active Comparator: Local anesthesia with tourniquet.
    • Lidocaine 1% was applied to the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc were injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Afterwards, a pneumatic tourniquet was placed at the level of the forearm at 250 mmHg after exsanguination with a bandage from Esmarch. The asepsis of the limb was continued, sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started. At the end of the surgical procedure, it was closed by planes, a soft bandage was placed, the tourniquet was removed and the patient was taken to recovery.

Clinical Trial Outcome Measures

Primary Measures

  • Procedure pain: Visual Analog Scale
    • Time Frame: immediate post surgery
    • Evaluated by Visual Analog Scale, A subjective psychometric response scale used to measure distinct behavioral or physiological phenomena based on linear numerical gradient, with values from 0 to 10. In the value 0 the absence or less intensity is located and in 10 the greater intensity of pain.

Secondary Measures

  • Bleeding
    • Time Frame: immediate post surgery
    • Bleeding estimated in consensus between anesthesiologist and surgeon, based on the gauze used during surgery
  • Anesthesia application time
    • Time Frame: at the beginning of the application of anesthesia
    • The interval of time in minutes that is required to apply the anesthetic method chosen in the area to be used

Participating in This Clinical Trial

Inclusion Criteria

  • Right holders of the Mexican Social Security Institute – Over 18 years – Trigger Finger Diagnosis – Diagnosis of Carpal Tunnel Syndrome – Diagnosis of Quervain Syndrome – Acceptance and signature of informed consent Exclusion Criteria:

  • Necessity for concomitant surgery – Previous surgeries on the injured site – Hemodynamic instability – History of peripheral vascular diseases – Do not wish to participate in the study – Hypersensitivity to medication – Smoking

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Instituto Mexicano del Seguro Social
  • Provider of Information About this Clinical Study
    • Principal Investigator: CLOTILDE FUENTES OROZCO, Investigador de tiempo completo – Instituto Mexicano del Seguro Social
  • Overall Official(s)
    • Clotilde Fuentes Orozco, PhD, Principal Investigator, Instituto Mexicano del Seguro Social

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.